Oncogenic TYK2P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade.
Woess K, Macho-Maschler S, Van Ingen Schenau DS, Butler M, Lassnig C, Valcanover D, Poelzl A, Meissl K, Maurer B, Brandstoetter T, Vogl C, Koren A, Kubicek S, Orlova A, Moriggl R, Strobl B, Sexl V, Van Leeuwen FN, Kuiper RP, Mueller M.
Woess K, et al. Among authors: kuiper rp.
Haematologica. 2022 Jan 13. doi: 10.3324/haematol.2021.279848. Online ahead of print.
Haematologica. 2022.
PMID: 35021603
Free article.